Daiichi Sankyo
Zachary Cain is an experienced leader in the field of oncology and medical affairs, currently serving as Executive Director and Global Medical Affairs Strategy Lead for Lung Cancer at Daiichi Sankyo, Inc. since September 2021. Prior to this role, Zachary spent over eleven years at Bristol Myers Squibb, progressing through various senior director and associate director positions focused on medical affairs and oncology. Zachary's earlier career includes a postdoctoral fellowship at Rutgers University following the completion of a PharmD degree at the University of Pittsburgh in 2009.
This person is not in any teams
This person is not in any offices
Daiichi Sankyo
21 followers
Daiichi Sankyo Co., Ltd. engages in the research, development, manufacture, and sale of pharmaceutical products. It operates through the following segments: Daiichi Sankyo Group and Ranbaxy Group. The Daiichi Sankyo Group segment comprises of Daiichi Sankyo Co., Ltd. and its subsidiaries. The Ranbaxy Group segment includes its core company, Ranbaxy Laboratories Ltd. Both group segments deal with business activities in prescription drugs and general pharmaceutical products. The company was founded on September 28, 2005 and is headquartered in Tokyo, Japan.